Actively Recruiting
Safety and Effectiveness of Tirofiban Treatment Guided by High-Resolution MRI in Adults with Late-Window Acute Ischemic Stroke
Led by Weifang Medical University · Updated on 2026-06-25
458
Participants Needed
1
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of high-resolution magnetic resonance vessel wall imaging HR-MRI to improve the diagnosis and treatment of acute ischemic stroke AIS patients who are beyond the typical treatment time window. This advanced imaging helps identify the cause of stroke by clearly showing arterial wall details and distinguishing intracranial atherosclerotic large artery atherosclerosis ICAS-LAA stroke from other types like cardiogenic embolism. The study aims to assess the safety and effectiveness of the drug tirofiban guided by HR-MRI in this specific group of stroke patients. Participants are randomly assigned to one of two groups. One group receives intravenous tirofiban starting within 30 minutes of randomization, with an initial bolus infusion followed by a continuous infusion for nearly 48 hours. Alongside tirofiban, they receive dual antiplatelet therapy aspirin and clopidogrel starting during the infusion and continuing for 21 days, followed by aspirin alone long-term. The other group receives only dual antiplatelet therapy for 21 days, followed by aspirin alone. The study compares these approaches to understand the benefits of adding tirofiban. During the trial, participants undergo assessments of their neurological status and functional independence using several scales, including the modified Rankin Scale mRS at around 90 days after randomization. Researchers monitor for improvements, side effects like intracranial hemorrhage, stroke recurrence, and mortality. The study includes safety evaluations within 24 hours after treatment starts, and participants are followed for outcomes over approximately three months. The trial is designed to provide evidence to optimize diagnosis and treatment for stroke patients beyond the usual time window.
CONDITIONS
Brief Title
HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)
Research Team
W
Weili Li, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here